(Total Views: 312)
Posted On: 11/18/2020 2:55:16 PM
Post# of 36567
Well, I guess we know the trial timeline, 6 months to 3 years in Phase 3.
Quote:
Task 7: Conduct Phase III clinical studies of Multivalent Ii-Key Peptide Vaccine in Large Population (26 weeks - 3 years) (Territories and countries where have a large Asian population, such as California and New York)
Conduct Large-scale immunization study in certain number of volunteers (number to be decided by regulatory authorities) to evaluate the safety, immune activation, and efficacy of the Ii-Key-SARS-CoV-2 Peptide Vaccine. The protocol will be designed to evaluate the safety and effectiveness of the vaccine to protect people from COVID-19 disease.
Milestone: Meet the product requirements of NMPA and the Department of Immunization of the National Health Commission to approve the production and sale of Ii-Key-SARS-CoV-2 peptide vaccine products.
(0)
(0)
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
